Hydroxychloroquine: the cornerstone of lupus therapy

1 Wallace DJ . The history of antimalarials. Lupus 1996; 5: S2 – S3 .

2 Fox R . Antimalarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus 1996; 5: S4 – S10 .

3 Kirou KA Lee C George S Louca K Peterson MGE Crow MK . Activation of the Interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005; 52: 1491 – 1503 .

4 The Canadian Hydroxychloroquine Study Group . A randomized study of the effect of withdrawing hydroxychloroquine sulphate in systemic lupus erythematosus. N Engl J Med 1991; 324: 150 – 154 .

5 Meinão IM Sato EI Andrade LEC Ferraz MB Atra E . Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus 1996; 5: 237 – 241 .

6 Williams HJ Egger MJ Singer JZ . Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J Rheumatol 1994; 21: 1457 – 1462 .

7 Levy RA Vilela VS Cataldo MJ . Hydroxychloroquine in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001; 10: 401 – 404 .

8 Clowse ME Magder L Witter F Petri M . Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006; 54: 3640 – 3647 .

9 Kasitanon N Fine DM Haas M Magder LS Petri M . Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 2006; 15: 366 – 370 .

10 James JA Kim-Howard XR Bruner BF . Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 2007; 16: 401 – 409 .

11 Wallace DJ Metzger AL Steicher VJ Turnbull BA Kern PA . The cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990; 89: 322 – 326 .

12 Petri M Lakatta C Magder L Goldman DW . Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994; 96: 254 – 259 .

13 Petri M . Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 1996; 5: S16 – S22 .

14 Tam LS Gladman D Hallett D Rahman P Urowitz MB . Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 2000; 27: 2142 – 2145 .

15 Wasko MC Hubert HB Lingala BV . Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007; 298: 187 – 193 .

16 Roman MJ Shanker BA Davis A . Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399 – 2406 .

17 Edwards MH Pierangeli S Liu X Barker JH Anderson G Harris EN . Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997; 96: 4380 – 4384 .

18 Espinola RG Pierangeli SS Gharavi AE Harris EN . Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002; 87: 518 – 522 .

19 Wallace DJ . Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? Arthritis Rheum 1987; 30: 1435 – 1436 .

20 Petri M . Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996; 25: 191 – 193 .

21 Erkan D Yazici Y Peterson MG Sammaritano L Lockshin MD . A cross-section study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology 2002; 41: 924 – 929 .

22 Ho KT Ahn CW Alarcon GS . Systemic lupus erythematosus in a mutiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology 2005; 44: 1303 – 1307 .

23 Mok CC Tang SSK To CH Petri M . Incidence and risk factors of thromboembolism in systemic lupus erythematosus. A comparison of three ethnic groups. Arthritis Rheum 2005; 52: 2774 – 2782 .

24 Ruiz-Irastorza G Egurbide MV Pijoan JI . Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006; 15: 577 – 583 .

25 Sotelo J Briceño E López-González MA . Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double blind, placebo-controlled trial. Ann Intern Med 2006; 144: 337 – 343 .

26 Ruiz-Irastorza G Ugarte A Egurbide MV . Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis 2007; 66: 815 – 817 .

27 Fessler BS Alarcón GS McGwin G . Systemic lupus erythematosus in three ethnic groups XVI: hydroxychloroquine usage is associated with a lower risk of damage accrual. Arthritis Rheum 2005; 52: 1473 - 1480 .

28 Alarcon GS McGwin G Bertoli AM . Effect of hydroxychloroquine in the survival of patients with systemic lupus erythematosus. data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007; 66: 1168 – 1172 .

29 Siso A Ramos-Casals M Bove A . Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus 2008 17: 281–288.

30 Costedoat-Chalumeau N Amoura Z Duhaut P . Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003; 48: 3207 – 3211 .